XTL BIOPHARMACEUTICALS Business Summary

XTL Biopharmaceuticals Ltd. (XTLB) operates as an intellectual property (IP) portfolio company, generating revenue through biopharmaceutical sublicensing and its web data subsidiary, The Social Proxy Ltd. As of February 2026, the company is executing a fundamental strategic transition following the insolvency filing of its web data unit and the acquisition of an 85% stake in NeuroNOS Ltd. from Beyond Air Inc. This transaction establishes NeuroNOS as XTLB’s flagship platform for autism and neuro-oncology, augmenting its Phase II-ready hCDR1 asset for Systemic Lupus Erythematosus (SLE). XTLB competes with GlaxoSmithKline and Aurinia Pharmaceuticals in the autoimmune sector, and Acadia Pharmaceuticals and Neuren Pharmaceuticals in the neuro-therapeutic market, positioning itself as a micro-cap IP aggregator focused on high-unmet-need clinical assets. The leadership team is anchored by CEO Noam Band, appointed in April 2025, who brings extensive experience in strategic business development and digital marketing from his previous roles as CEO of Gix Internet and Dotomi. Chairman Shlomo Shalev provides continuity in international venture capital and corporate governance, while Director of Finance Niv Segal oversees the company’s fiscal restructuring and Nasdaq compliance efforts. A key strategic stakeholder is Beyond Air Inc., which holds a 19.9% equity stake following the NeuroNOS transaction. The board is further supported by veteran investor Alexander Rabinovitch, whose expertise in Israeli capital markets is central to the company’s ongoing private placement initiatives and efforts to stabilize stockholders' equity.